Efficacy of deferasirox in North Indian β-thalassemia major patients: A preliminary report

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 1, 2012, Pages 51-53

  Panigrahi, Inusha ^a   Vaidya, Pankaj C ^a   Bansal, Deepak ^a   Marwaha, Ram K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

adverse effects; hemoglobinopathies; iron chelation; safety; transfusions

Indexed keywords

AMINOTRANSFERASE; CREATININE; DEFERASIROX; FERRITIN; HEMOGLOBIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INDIA; LEG CRAMP; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SCHOOL CHILD; SEX RATIO; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; MALE; TRIAZOLES;

EID: 84855470314     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182374142     Document Type: Article

References (14)

1. Cappellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med. 2008;8:663-674.
2. Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev. 2008;22(suppl 2):S35-S41.
3. Choudhry VP, Naithani R. Current status of iron overload and chelation with deferasirox. Indian J Pediatr. 2007;74: 759-764. (Pubitemid 350029380)
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89: 1187-1193. (Pubitemid 39390442)
5. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2006;136:501-508. (Pubitemid 46046309)
6. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95:557-566.
7. Chandra J, Choudhary H, Pemde H, et al. Safety and efficacy of deferasirox in multitransfused Indian children with b-thalassaemia major. Ann Trop Paediatr. 2011;31:47-51.
8. Viprakasit V, Ibrahim H, Ha S-Y, et al. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. Int J Hematol. 2011;93:319-328.
9. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with b-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-465.
10. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752-759.
11. Agarwal MB. Deferasirox:oral, once daily iron chelator-an expert opinion. Indian J Pediatr. 2010;77:185-191.
12. Chang H-H, Lu M-Y, Liao Y-M, et al. Improved efficacy and tolerability of oral deferasirox by twice daily dosing for patients with transfusion dependent b-thalassemia. Pediatr Blood Cancer. 2011;56:420-424.
13. Angelluci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haema-tologica. 2008;93:741-752. (Pubitemid 351669315)
14. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006;30:329-347.